Contact
    Start Publications Therapeutic treatment of Zika virus infection using a ...
    ←  Publication Finder
    Attension

    Therapeutic treatment of Zika virus infection using a brain-penetrating antiviral peptide

    Year: 2018

    Journal: Nat. Mater., Volume 17, NOV, page 971

    Authors: Jackman, Joshua A.; Costa, Vivian V.; Park, Soohyun; Real, Ana Luiza C., V; Park, Jae Hyeon; Cardozo, Pablo L.; Ferhan, Abdul Rahim; Olmo, Isabella G.; Moreira, Thaiane P.; Bambirra, Jordana L.; Queiroz, Victoria F.; Queiroz-Junior, Celso M.; Foureaux, Giselle; Souza, Danielle G.; Ribeiros, Fabiola M.; Yoon, Bo Kyeong; Wynendaele, Evelien; De Spiegeleer, Bart; Teixeira, Mauro M.; Cho, Nam-Joon

    Organizations: National Research Foundation of Singapore [NRF-NRFF2011-01, NRF-CRP10-2012-07, NRF2015NRF-POC0001-19]; National Medical Research Council of Singapore [NMRC/CBRG/0005/2012]; Centre for Precision Biology at Nanyang Technological University; National Institute of Science and Technology in Dengue and Host-microorganism Interaction (INCT dengue) - Brazilian National Science Council (CNPq, Brazil); Minas Gerais Foundation for Science (FAPEMIG, Brazil); Financiadora de Estudos ePesquisa (Brazil) [FINEP 01.16.0050.00]; Comissao de Apoio a Pessoal de Ensino Superior (CAPES, Brazil); [PP SUS: APQ-03744-17]

    Zika virus is a mosquito-borne virus that is associated with neurodegenerative diseases, including Guillain-Barre syndrome' and congenital Zika syndrome(2). As Zika virus targets the nervous system, there is an urgent need to develop therapeutic strategies that inhibit Zika virus infection in the brain. Here, we have engineered a brain-penetrating peptide that works against Zika virus and other mosquito-borne viruses. We evaluated the therapeutic efficacy of the peptide in a lethal Zika virus mouse model exhibiting systemic and brain infection. Therapeutic treatment protected against mortality and markedly reduced clinical symptoms, viral loads and neuroinflammation, as well as mitigated microgliosis, neurodegeneration and brain damage. In addition to controlling systemic infection, the peptide crossed the blood-brain barrier to reduce viral loads in the brain and protected against Zikavirus-induced blood-brain barrier injury. Our findings demonstrate how engineering strategies can be applied to develop peptide therapeutics and support the potential of a brain-penetrating peptide to treat neurotropic viral infections.
    View publication